We evaluated the immunogenicity , safety and clinical effectiveness of an MF59 ( ) - adjuvanted trivalent influenza vaccine ( aTIV ) compared with a non-adjuvanted vaccine ( TIV ) in subjects 65 years old , with or without co-morbidities .